» Articles » PMID: 24445520

Colorectal Cancer in 2013: Towards Improved Drugs, Combinations and Patient Selection

Overview
Specialty Oncology
Date 2014 Jan 22
PMID 24445520
Citations 28
Authors
Affiliations
Soon will be listed here.
Citing Articles

β-carboline derivative Z86 attenuates colorectal cancer cell proliferation and migration by directly targeting PI3K.

Nie S, Chang L, Huang Y, Zhou H, Yang Q, Kong L Nat Prod Bioprospect. 2024; 14(1):3.

PMID: 38169019 PMC: 10761647. DOI: 10.1007/s13659-023-00422-y.


Prediction of histone deacetylase inhibition by triazole compounds based on artificial intelligence.

Wang Y, Zhang P Front Pharmacol. 2023; 14:1260349.

PMID: 38035010 PMC: 10684768. DOI: 10.3389/fphar.2023.1260349.


Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.

Zhao L, Li Q, Huang Z, Sun M, Lu J, Zhang X Cell Death Dis. 2021; 12(11):974.

PMID: 34671018 PMC: 8528846. DOI: 10.1038/s41419-021-04267-6.


The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer.

Liang L, Lin R, Xie Y, Lin H, Shao F, Rui W Int J Biol Sci. 2021; 17(10):2548-2560.

PMID: 34326693 PMC: 8315013. DOI: 10.7150/ijbs.58671.


Targeting LncRNA EPIC1 to inhibit human colon cancer cell progression.

Wu Q, Wei J, Zhao C, Xiang S, Shi M, Wang Y Aging (Albany NY). 2020; 15(2):583-594.

PMID: 33170148 PMC: 9925677. DOI: 10.18632/aging.103790.


References
1.
Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y . Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol. 2013; 31(10):1341-7. DOI: 10.1200/JCO.2012.45.1930. View

2.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

3.
Sadanandam A, Lyssiotis C, Homicsko K, Collisson E, Gibb W, Wullschleger S . A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013; 19(5):619-25. PMC: 3774607. DOI: 10.1038/nm.3175. View

4.
Schmoll H, Cunningham D, Sobrero A, Karapetis C, Rougier P, Koski S . Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012; 30(29):3588-95. DOI: 10.1200/JCO.2012.42.5355. View

5.
Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E . Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2012; 14(1):29-37. DOI: 10.1016/S1470-2045(12)70477-1. View